A Study of Paliperidone Palmitate 6-Month Formulation
Status:
Active, not recruiting
Trial end date:
2022-05-06
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the long-term safety and tolerability of
paliperidone 6-month PP6M (Dose 1 or Dose 2 [milligram] mg eq.) and to provide access to PP6M
in participants with schizophrenia completing the R092670PSY3015 study without relapse.